| 1. |
2022
Chang CL,Lin YJ,Pan CC,Kuo CN.
Effectiveness and Safety of Lower Dose of Rivaroxaban for Cancer-Related Venous Thromboembolism: A Retrospective Cohort Study
. Annals of Pharmacotherapy
.2022
;(56):1308-1314
|
|
| 2. |
2022
Mugiyanto E,Adikusuma W,Irham LM,Huang WC,Chang WC,Kuo CN.
Integrated genomic analysis to identify druggable targets for pancreatic cancer
. Frontiers in Oncology
.2022
;(12):989077-989077
|
|
| 3. |
2021
Lin YJ,Kuo ChN,Ko Y.
Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
. Breast
.2021
;(57):18-24
|
|
| 4. |
2021
Chen KJ,Tai YT,Chang E,Kuo LN,Kuo CN.
Effectiveness of collaboration between oncology pharmacists and anaesthesiologists for inpatient cancer pain management: A pilot study in Taiwan
. Journal of International Medical Research
.2021
;(49):3000605211055415-3000605211055415
|
|
| 5. |
2020
Liu YM,Kuo CN,Liou JP.
Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)
. Expert Opinion on Therapeutic Patents
.2020
;(30):351-373
|
|
| 6. |
2020
Kuo CN,Liao YM,Kuo LN,Tsai HJ,Chang WC,Yen Y.
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
. Journal of the Formosan Medical Association
.2020
;(119):1731-1741
|
|
| 7. |
2020
Wang LC,Kuo CN,Ko Y.
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast cancer in Taiwan
. Breast Journal
.2020
;(26):2099-2102
|
|
| 8. |
2019
Wakabayashi G,Lee YC,Luh F,Kuo CN,Chang WC,Yen Y.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
. Journal of Biomedical Science
.2019
;(26)
|
|
| 9. |
2018
Kuo CN,Pan JJ,Huang YW,Tsai HJ,Chang WC.
Association between nonsteroidal anti-inflammatory drugs and colorectal cancer: A population-based case-control study
. Cancer Epidemiology Biomarkers and Prevention
.2018
;(27):737-745
|
|